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Summary
Background: Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV repli-
cation. Novel anti-viral drugs have shown potent HBV RNA decline without concomi-
tant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment 
response is yet unclear.
Aim: To study the degree of on-treatment viral antigen decline among patients with 
pronounced HBV RNA decrease in relation to off-treatment sustained response and 
HBsAg loss.
Methods: HBV RNA, HBsAg and hepatitis B core-related antigen (HBcrAg) were 
quantified in patients with chronic hepatitis B who participated in two randomised 
controlled trials of peginterferon-based therapy. Sustained response (HBV DNA 
<2000 IU/mL) and/or HBsAg loss were assessed in patients with and without on-
treatment HBV RNA response (either >2 log HBV RNA decline or >1 log decline re-
sulting in an undetectable value at on-treatment week 24), stratified by concomitant 
HBsAg decline (<0.5/0.5-1/>1 log).
Results: We enrolled 279 patients; 176 were hepatitis B e antigen (HBeAg)-positive, 
and 103 were HBeAg-negative. Sustained response was achieved in 20.4% of pa-
tients. At on-treatment week 24, HBV RNA response was associated with higher 
sustained response rates (27.4% vs 13.0% in non-responders, P =  0.004). However, 
among patients with an HBV RNA response (n = 135), 56.4% did not experience >0.5 
log HBsAg decline. Among HBV RNA responders, sustained response was achieved 
in 47.6% of those with >1 log HBsAg decline (n = 20/42), vs 16.0% with <0.5 log 
decline (n = 12/75, P = 0.001). Similar results were obtained with HBcrAg and when 
response was defined as HBsAg loss.
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1  | INTRODUC TION
Chronic hepatitis B (CHB) infection is one of the main causes of end-
stage liver disease and hepatocellular carcinoma (HCC).1 The optimal 
goal of anti-viral treatment is the achievement of an off-treatment 
sustained response to reduce the incidence of HCC and limit the 
progression of liver disease.2 However, this remains difficult to 
achieve, as covalently closed circular DNA (cccDNA) persists in the 
hepatocytes.3-5 On-treatment maintained viral suppression is there-
fore a second-best alternative.
While novel compounds are emerging, current therapeutic op-
tions are still limited to nucleo(s)tide analogues (NAs) and pegylated 
interferon (PEG-IFN). Nucleo(s)tide analogues are well tolerated and 
suppress HBV replication effectively.6 Nonetheless, nucleo(s)tide 
analogues do not directly affect cccDNA7 and are therefore associ-
ated with a limited off-treatment sustained response rate.8,9 A finite 
duration of PEG-IFN can result in higher sustained response rates, as 
it is able to inhibit HBV transcription and reduces the production of 
viral particles through targeting cccDNA.10 However, sustained re-
sponse is only achieved in a limited proportion of patients.10-12 PEG-
IFN therapy is currently experiencing a revival, as it may be more 
effective when combined with novel anti-virals.13,14
Eradication of intrahepatic cccDNA is considered to be a crucial 
step in the clearance of the hepatitis B virus (HBV), and monitoring 
its kinetics during therapy is highly desirable. However, cccDNA can 
only accurately be quantified invasively by liver biopsy. Therefore, 
non-invasive serological markers that correlate with intrahepatic 
replicative activity of HBV are needed to assess the efficacy of 
(novel) anti-viral agents in CHB patients.
Recently, hepatitis B virus (HBV) RNA has emerged as a potential 
prognostic biomarker for treatment response, as it correlates with 
transcriptional activity of cccDNA and therefore may reflect intrahe-
patic replication activity.15-18 Recent studies suggest that a decline in 
serum HBV RNA levels during treatment with nucleo(s)tide analogues 
or PEG-IFN is associated with treatment response, although overall de-
clines during treatment were limited.19-24 Interestingly, recent phase 1 
studies of novel capsid assembly modifiers have shown substantially 
stronger HBV RNA declines, which has been interpreted as a possible 
sign of a more potent effect on the intrahepatic HBV reservoir.25
However, besides the observed decline in serum HBV RNA during 
capsid assembly modifiers therapy, little changes in hepatitis B sur-
face antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) 
concentrations were observed in these patients.25 How this relates 
to long-term off-treatment response is yet unclear.26 We therefore 
aimed to study the degree of on-treatment HBsAg and HBcrAg de-
cline among patients with pronounced HBV RNA decrease, both in 
relation to off-treatment sustained response and HBsAg loss.
2  | PATIENTS AND METHODS
2.1 | Study population
For the current study, we enrolled chronic hepatitis B (CHB) patients 
who participated in two global randomised controlled trials (the 
99-01 and PARC study; trial registration numbers NCT00114361 
and NCT00146705). Detailed information regarding inclusion crite-
ria and study design have been described elsewhere.27,28 In short, 
the 99-01 study enrolled hepatitis B e antigen (HBeAg)-positive 
patients (n = 266), who were randomised to treatment with PEG-
IFN alpha-2b 100 µg/week plus lamivudine 100 mg/day or PEG-IFN 
plus placebo for 52 weeks.27 In the PARC study, HBeAg-negative 
patients (n = 133) were treated with PEG-IFN alpha-2a 180 µg/week 
monotherapy or PEG-IFN combination therapy with the addition of 
ribavirin 1000-2000 mg for 48 weeks.28 Response was assessed at 
6 months after therapy discontinuation (end of follow-up; EOF). For 
both studies, eligible patients had been HBsAg positive for at least 
6 months, had a serum HBV DNA level of more than 10 000 copies/
mL (equals ± 2000 IU/mL) and an elevated ALT greater than 1.5-2 
times the upper limit of normal (ULN) within 8 weeks before ran-
domisation. The original study protocols were in line with the ethical 
guidelines of the 1975 Declaration of Helsinki and approved by the 
medical ethical committees. Both the 99-01 and PARC studies dem-
onstrated that combination therapy was not superior to PEG-IFN 
monotherapy, and data were therefore pooled for the current analy-
sis.27,28 For the current study we selected patients from the original 
studies if data were available for our primary outcome (sustained 
response) and a baseline HBV RNA measurement was available.
2.2 | Serum HBV RNA, HBsAg and HBcrAg 
quantification
HBV RNA was quantified from serum samples using rapid amplifi-
cation of complimentary DNA (cDNA)-ends (RACE)-based real-time 
polymerase chain reaction (PCR) at a central laboratory (University 
Conclusions: In this cohort, many patients with HBV RNA response during peginter-
feron-based treatment did not experience HBsAg and/or HBcrAg decline. The ab-
sence of concomitant decline in these viral antigens was associated with low rates of 
treatment response and HBsAg loss. Future trials should therefore consider kinetics 
of combined biomarkers to assess anti-viral efficacy.
Trial registration, ClinicalTrials.gov: NCT00114361, NCT00146705.
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Hospital Leipzig, Germany). The PCR technique has been described 
previously.19 The lower limit of detection (LOD) for HBV RNA in 
this assay was 800 copies/millilitre (c/mL).29 Quantitative HBsAg 
levels were assessed using Abbott Architect (Abbott, Abbott Park, 
IL). The assay's LOD for HBsAg levels was 0.05 IU/mL. HBcrAg was 
quantified using the Lumipulse® G HBcrAg assay (Fujirebio Europe). 
The LOD of HBcrAg measurements was 100 U/mL (2 log U/mL).30 
As HBcrAg partially depends on HBeAg-status and is low or un-
detectable in most HBeAg-negative patients during therapy,30 the 
relationship between HBcrAg and response was assessed in the 
HBeAg-positive subgroup only.
2.3 | Endpoints
Primary outcomes were sustained response and HBsAg loss. 
Sustained response was defined as HBV DNA <2000 IU/mL 
6 months after end of treatment. HBsAg loss was assessed at end of 
follow-up and during long-term follow-up.23,27,28 HBV RNA, HBsAg 
and HBcrAg levels were measured at baseline, on-treatment week 
12, on-treatment week 24, end of treatment (EOT) and during fol-
low-up. HBV RNA response was defined as HBV RNA decline of ei-
ther >2 log or an HBV RNA decline or >1 log which resulted in HBV 
RNA level below the LOD. HBsAg decline was categorised as <0.5 
log, 0.5-1 log and >1 log. HBcrAg decline was categorised as <1 log, 
1-3 log and >3 log. For this study, we assessed HBV RNA response 
and concomitant HBsAg or HBcrAg decline at on-treatment week 
24. For sensitivity analysis, HBV RNA response at different time 
points (on-treatment week 12 and EOT) and in different subgroups 
(HBeAg-status and type of treatment) was also assessed.
2.4 | Statistical analysis
Statistical analysis was performed using IBM SPSS for Windows ver-
sion 25.0 (SPSS Inc). Descriptive data were reported as percentages, 
means (±standard deviation; SD) and medians (with interquartile 
range; IQR) when appropriate. Data were tested for significance 
using chi-squared test, Fisher's exact test or student's t-test where 
appropriate. Univariate logistic regression analysis was used to es-
timate odds ratios (ORs) of HBsAg decline for sustained response 
in patients with HBV RNA response at on-treatment week 24. 
Differences were considered statistically significant when P ≤ 0.05. 
Graphic representation of the results was performed using Graph 
Pad Prism version 5 for Windows (GraphPad Software).
3  | RESULTS
3.1 | Patient characteristics
This study included 279 patients; 176 HBeAg-positive, 103 HBeAg-
negative. Baseline characteristics of these patients are displayed in 
Table 1. Mean baseline HBV RNA levels were 5.9 log c/mL (±1.6) in 
the overall study population. HBV RNA levels were higher in HBeAg-
positive patients; 6.8 log c/mL (±1.2) compared to 4.3 log c/mL (±0.9) 
in HBeAg-negative patients. Baseline HBV RNA levels were already 
below the LOD in 12 patients (4.3%). Mean quantitative HBsAg lev-
els were 4.2 log IU/mL (±0.7) at baseline. In HBeAg-positive patients 
mean baseline HBcrAg levels were 8.3 log U/mL (±0.7). In the overall 
population, sustained response was achieved in 57 patients (20.4%) 
and HBsAg loss in 18 patients (6.5%).
3.2 | On-treatment HBV RNA response is 
associated with sustained response and HBsAg loss
HBV RNA data at on-treatment week 24 were available in 258/279 
patients. Of those, 135 experienced an HBV RNA response (52.3%) 
at week 24 of therapy. Patients with an HBV RNA response had 







Age at inclusion, years 
(median, IQR)
32 (23-41) 41 (33-50)
Male (n, %) 135 (76.7) 74 (71.8)
Race (n, %)
Caucasian 116 (65.9) 98 (95.1)
Asian 43 (24.4) 3 (2.9)
Other 17 (9.7) 2 (1.9)
HBV genotype (n, %)
A 53 (30.1) 15 (14.6)
B 18 (10.2) 0 (0)
C 35 (19.9) 2 (1.9)
D 64 (36.5) 81 (78.6)
Other 6 (3.4) 5 (4.9)
Study treatment (n, %)
PEG-IFN mono 86 (48.9) 52 (50.5)
PEG-IFN + LAM 90 (51.1) NA
PEG-IFN + RBV NA 51 (49.5)
Laboratory results at baseline
HBV RNAa  (mean, ±SD) 6.8 (1.2) 4.3 (0.9)
HBsAgb  (mean, ±SD) 4.4 (0.7) 3.8 (0.5)
HBV DNAb  (mean, ±SD) 8.3 (1.0) 6.0 (1.2)
HbcrAgc  (mean, ±SD) 8.3 (0.7) 5.1 (1.2)
Abbreviations: HBcrAg, hepatitis B core-related antigen; HBeAg, 
hepatitis B e antigen; HBsAg, quantitative hepatitis B surface antigen; 
HBV, hepatitis B virus; IQR, interquartile range; LAM, lamivudine; n, 
number; NA, not applicable; PEG-IFN, peginterferon; RBV, ribavirin; SD, 
standard deviation.
aLogarithmic scale, copies/mL. 
bLogarithmic scale, IU/mL. 
cLogarithmic scale, U/mL. 
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significantly higher rates of sustained response and HBsAg loss 
(Figure 1A). Among 135 patients with an HBV RNA response, sus-
tained response was observed in 37 patients (27.4%) and HBsAg loss 
in 14 patients (10.4%). In contrast, of the 124 patients who did not 
experience an HBV RNA response, only 16 patients achieved sus-
tained response (13.0%) and 1 patient achieved HBsAg loss (0.8%; 
P = 0.004 for sustained response and P = 0.001 for HBsAg loss).
Similar results were obtained after stratification by HBeAg-status. 
Among the HBeAg-positive patients with an HBV RNA response 
(n = 85, 54.1%), sustained response was observed in 20 (23.5%) and 
HBsAg loss in 10 patients (11.8%). In contrast, of the 72 patients 
(45.9%) who did not experience an HBV RNA response, only seven 
(9.7%) achieved sustained response and none (0.0%) achieved HBsAg 
loss (P = 0.022 for sustained response and P = 0.003 for HBsAg loss). 
Among the HBeAg-negative patients with an HBV RNA response 
(n = 50, 49.5%), 17 patients (34.0%) achieved sustained response and 
four patients (8.0%) achieved HBsAg loss. In contrast, of the 51 pa-
tients (50.5%) without an HBV RNA response, sustained response was 
observed in only nine patients (17.6%) and HBsAg loss in one patient 
(2.0%; P = 0.060 for sustained response and P = 0.162 for HBsAg loss).
Similar results were obtained when HBV RNA response was as-
sessed at on-treatment week 12 or at end-of-treatment.
3.3 | Low response rates in the absence of HBsAg 
decline in patients with HBV RNA response
Among the 135 patients with an HBV RNA response at on-treatment 
week 24, HBsAg data were available in 133 patients. Among patients 
F I G U R E  1   (A) Rates of sustained response (HBV DNA 
<2000 IU/mL) and hepatitis B surface antigen (HBsAg) loss in 
patients with and without hepatitis B virus (HBV) RNA response at 
on-treatment week 24 (n = 258). (B) Rates of sustained response 
and HBsAg loss in subgroup of patients with HBV RNA response at 
on-treatment week 24 (n = 133), stratified by HBsAg decline (<0.5, 
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0 F I G U R E  2   (A) Hepatitis B surface antigen (HBsAg) decline 
during treatment and follow-up in patients with an hepatitis B 
virus (HBV) RNA response at on-treatment week 24, stratified 
by patients with and without sustained response (HBV DNA 
<2000 IU/mL; SR). (B) Hepatitis B core-related antigen (HBcrAg) 
decline during treatment and follow-up in patients with an HBV 
RNA response at on-treatment week 24, stratified by patients with 
and without SR. Assessed in patients with positive hepatitis B e 
antigen (HBeAg) at baseline. P-value for comparison at week 24. BL, 
baseline; EOF, end of follow-up; EOT, end of treatment; HBcrAg, 
hepatitis B core-related antigen; HBsAg, hepatitis B surface 
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with an HBV RNA response, a more prominent decline in HBsAg was 
observed in those who achieved sustained response, compared to 
those who did not (Figure 2A); mean HBsAg declines were 1.7 vs 0.6 
log IU/mL (P = 0.001, Figure 1B), with an OR of 1.779 (P < 0.001).
Among the 133 HBV RNA responders, 75 patients (56.4%) did 
not experience at least 0.5 log HBsAg decline at that same time 
point. Of those 75 patients, only 12 achieved sustained response 
(16.0%) and one achieved HBsAg loss (1.3%). Of the 42 patients 
(31.2%) with a concomitant HBsAg decline of more than 1 log, sus-
tained response was achieved in 20 patients (47.6%) and HBsAg loss 
in 12 patients (28.6%; P ≤ 0.001).
Similar results were obtained when data were stratified accord-
ing to HBeAg-status at baseline. HBV RNA response at on-treatment 
week 24 was observed in 85/157 HBeAg-positive (54.1%) and in 
50/101 HBeAg-negative (49.5%) patients. Among the 85 HBeAg-
positive patients with an HBV RNA response, sustained response 
rates were 10.8% in patients with HBsAg decline of <0.5 log vs 
42.4% in patients with >1 log HBsAg decline; HBsAg loss rates were 
0.0% vs 30.3% (P = 0.006 for sustained response and P < 0.001 for 
HBsAg loss). Among the 50 HBeAg-negative patients with an HBV 
RNA response, sustained response rates were 21.1% (with HBsAg 
decline <0.5 log) vs 66.7% (with HBsAg decline >1 log); and HBsAg 
loss rates were 2.6% vs 22.2% (P = 0.002 for sustained response and 
P = 0.037 for HBsAg loss). Findings were also consistent when anal-
yses were limited to patients treated with PEG-IFN monotherapy; 
sustained response rates were 18.0% in patients with HBsAg decline 
<0.5 log, vs 65.2% in patients with HBsAg decline >1 log; HBsAg 
loss rates were 2.0% vs 30.4% (P ≤ 0.001).
3.4 | Low response rates in the absence of HBcrAg 
decline in HBeAg-positive patients with HBV 
RNA response
In the 157 HBeAg-positive patients HBV RNA response was observed 
in 85 patients (54.1%) at on-treatment week 24. HBV RNA responders 
who achieved sustained response showed a more prominent on-treat-
ment decrease in HBcrAg than those who did not (Figure 2B); mean 
declines were 2.7 vs 1.9 log U/mL at week 24 (P = 0.002, Figure 2).
Of the 85 patients with an HBV RNA response at week 24, 79 
had HBcrAg data available. A total of 14 patients (17.7%) did not 
experience at least 1 log HBcrAg decline, of whom only one (7.1%) 
achieved sustained response and HBsAg loss (Figure 3). Conversely, 
sustained response was observed in 69.2% (9/13) and HBsAg loss in 
53.8% (7/13) of the patients with >3 log HBcrAg decline (P < 0.001 
for both sustained response and HBsAg loss).
4  | DISCUSSION
The current study, a pooled analysis of two randomised trials, 
confirms that on-treatment HBV RNA decline is associated with 
higher rates of sustained off-treatment response and HBsAg loss 
in patients treated with finite PEG-IFN-based treatment regimens. 
However, many patients with HBV RNA decrease did not experience 
a decline in the viral antigens HBsAg and/or HBcrAg. In our study, 
treatment response was predominantly observed in patients with 
both HBV RNA and viral antigen decline, whereas response rates in 
patients without concomitant viral antigen decrease were very low. 
These findings suggest that combinations of biomarkers should be 
used to ascertain a clinically relevant response to anti-viral therapy 
and may have important implications for the interpretation of the 
anti-viral efficacy of novel anti-viral agents, such as capsid assembly 
modifiers.
In the past years, several viral biomarkers have been identi-
fied that may be used to estimate the probability of response to 
F I G U R E  3   (A) Rates of sustained response (HBV DNA 
<2000 IU/mL) and hepatitis B surface antigen (HBsAg) loss in 
patients with and without hepatitis B virus (HBV) RNA response at 
on-treatment week 24. Assessed in patients with positive hepatitis 
B e antigen (HBeAg) at baseline (n = 157). (B) Rates of sustained 
response and HBsAg loss in subgroup of patients with HBV RNA 
response at on-treatment week 24 (n = 79), stratified by hepatitis B 
core-related antigen (HBcrAg) decline (<1, 1-3 or >3 log). Assessed 
in patients with positive HBeAg at baseline. HBcrAg, hepatitis B 
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anti-viral therapy, possibly through correlations with intrahepatic 
HBV transcriptional activity. Examples include serum levels of 
viral antigens, such as HBsAg, HBeAg and HBcrAg, and more re-
cently also serum levels of HBV RNA. It is important to note that 
the intrahepatic cccDNA acts as a template for all of these bio-
markers through transcription of four overlapping open reading 
frames (ORFs). Each ORF encodes for a subtype of polyadenylated 
RNAs, which subsequently serve as templates for the transcrip-
tion of a number of proteins.31,32 Their relative expression may be 
influenced by many factors, including host immune responses and 
anti-viral therapy. Interpretation of kinetics of a single biomarker 
may therefore be misleading if changes in other biomarkers are 
not considered.
The potential advantage of HBV RNA as a biomarker is based 
on the assumption that serum HBV RNA levels reflect an early step 
in the HBV replication process. A decline of HBV RNA levels has 
therefore been postulated to directly reflect a decrease in HBV 
transcriptional activity, either through a reduction in the cccDNA 
template or inhibition of transcriptional activity. This phenomenon is 
elegantly demonstrated by studies that show potent HBV DNA, but 
limited HBV RNA, decreases with NA therapy,21,33 since NA therapy 
does not influence HBV RNA production nor the cccDNA reservoir.7 
On the other hand, among the few patients experiencing significant 
HBV RNA declines during treatment with nucleo(s)tide analogues 
or PEG-IFN, HBV RNA decline was associated with higher rates of 
off-treatment sustained response.18,20,21,24,33
Interestingly, two preliminary reports of recent studies in pa-
tients treated with novel capsid assembly modifiers have demon-
strated superior HBV RNA declines.13,25 Whether these declines 
also translate to higher rates of off-treatment sustained response 
remains to be determined as off-treatment data have not yet been 
reported. Importantly, both studies showed virtually no declines 
in viral antigens such as HBsAg and HBcrAg, despite the potent 
effects on HBV RNA. This apparent disconnection between the 
different markers may be accounted for by the relative short treat-
ment duration of capsid assembly modifiers in experiment trials, 
as well as the different mode of action of the capsid assembly 
modifiers, which may have direct effects on HBV RNA production 
while not interfering with viral antigen production. The observed 
decrease in HBV RNA may therefore not reflect cccDNA decline. 
Until now, it has been unclear how such a response, i.e. a strong 
HBV RNA decline but with persistently high levels of viral anti-
gens, relates to the prospect of subsequent treatment response.
Our study shows to the best of our knowledge for the first time 
that many patients experiencing HBV RNA decline during treatment 
with conventional anti-viral agents do not experience concomitant 
decreases in HBsAg and HBcrAg. In this cohort, response rates were 
extremely low in this group, underscoring the complex interplay 
between these biomarkers. These findings may have important im-
plications for studies evaluating novel anti-viral agents, in particular 
the capsid assembly modifiers and other agents interfering with HBV 
RNA production, as it appears that HBV RNA decline itself might not 
be an adequate predictor of sustained response. We therefore argue 
that HBV RNA decline should not be used as a primary endpoint for 
treatment trials.
Strengths of our study include the large and very well-character-
ised patient sample enrolled from two global randomised trials and 
the availability of data on a wide range of biomarkers. We were also 
able to assess both sustained response and HBsAg loss. However, 
despite the large number of patients, subgroup analysis did limit the 
number of available cases per group. Nevertheless, our findings were 
consistent when separately analysing patients according to HBeAg-
status or treatment regime. However, validation of our findings 
among these subgroups, as well as confirmation of our hypothesis 
on the applicability to novel agents, warrants further investigation.
In conclusion, HBV RNA decline without concomitant viral anti-
gen (HBsAg and/or HBcrAg) decline is associated with low off-treat-
ment sustained response rates an HBsAg loss. Combinations of viral 
markers should be used to accurately assess response to anti-viral 
therapy.
ACKNOWLEDG EMENTS
We extend our sincere thanks and gratitude to N. Erler, PhD, statisti-
cian, for her advice, valuable comments and suggestions that ben-
efited the statistical analysis of our study. All authors reviewed and 
approved the final manuscript.
Declaration of personal interests: SB received an unrestricted re-
search grant from Gilead. AB has been received research grants from 
Roche, Gilead Sciences, Fujirebio, and Janssen. RdK has received 
honoraria for consulting/speaking from Gilead, Janssen, AbbVie 
and Norgine and received research grants form Gilead and Janssen. 
FvB has received research support and provided consultancy for 
Roche. TB has received research support, consulting and/or speak-
ing fees from Gilead, Roche, Merck, AbbVie, Bristol-Myers Squibb 
and Janssen. BH has received research support and consultancy 
fees from Intercept, Cymabay, Genfit, Mirum, Albireo, Calliditas 
and Chemomab. HJ has received research support, consulting and/
or speaking fees from Gilead, Roche, Merck, AbbVie, Bristol-Myers 
Squibb, Arbutus, Janssen and MedImmune. MS has received speak-
er's fees and research support from Roche, Innogenetics, BMS and 
Fujirebio. The other authors report no disclosures.
AUTHORSHIP
Guarantor of the article: None.
Author contributions: MS, SB, RdM and HLAJ conceived the 
study. SB and MS performed statistical analysis. SB and MS made 
graphic images, interpretation of data and revision of the manu-
script. SB wrote the manuscript, which was revised by all authors.
ORCID
Sylvia M. Brakenhoff  https://orcid.org/0000-0001-7687-4036 
Margo J. H. van Campenhout  https://orcid.
org/0000-0003-0460-4920 
Robert J. de Knegt  https://orcid.org/0000-0003-0934-6975 
Florian van Bömmel  https://orcid.org/0000-0003-2679-0672 
Milan J. Sonneveld  https://orcid.org/0000-0002-9253-563X 
320  |     BRAKENHOFF Et Al.
R E FE R E N C E S
 1. World Health Organization. Hepatitis B factsheet. 2019, updated 
18–07-2019 [Access Date 18–05-2020].
 2. Martinez MG, Testoni B, Zoulim F. Biological basis for functional 
cure of chronic hepatitis B. J Viral Hepat. 2019;26:786-794.
 3. Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and 
HDV infection. J Hepatol. 2016;65:835-848.
 4. Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA–the holy 
grail to hepatitis B cure. J Hepatol. 2016;64:S41-S48.
 5. Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. 
Clinical implications of hepatitis B Virus RNA and covalently closed 
circular DNA in monitoring patients with chronic hepatitis B today 
with a gaze into the future: the field is unprepared for a sterilizing 
cure. Genes (Basel). 2018;9:483.
 6. Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and ef-
ficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 
2018;38:84-89.
 7. Lopatin U. Drugs in the pipeline for HBV. Clin Liver Dis. 2019;23: 
535-555.
 8. Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of re-
sponse to entecavir therapy in hepatitis B e antigen-negative 
chronic hepatitis B patients. Hepatology. 2013;58:1888-1896.
 9. Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. 
Discontinuation of oral antivirals in chronic hepatitis B: a systematic 
review. Hepatology. 2016;63:1481-1492.
 10. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon 
alpha-2b plus adefovir induce strong cccDNA decline and HBsAg 
reduction in patients with chronic hepatitis B. Hepatology. 
2006;44:675-684.
 11. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivu-
dine, and the combination for HBeAg-positive chronic hepatitis B. 
N Engl J Med. 2005;352:2682-2695.
 12. Zhou Y, Yan R, Ru GQ, Yu LL, Yao J, Wang H. Pegylated-interferon 
consolidation treatment versus nucleos(t)ide analogue consolida-
tion treatment in non-cirrhotic hepatitis B patients with hepatitis 
B e antigen seroconversion: an open-label pilot trial. Hepatol Int. 
2019;13:422-430.
 13. Yuen MF, Gane EJ, Kim DJ, et al. Antiviral activity, safety, and phar-
macokinetics of capsid assembly modulator NVR 3–778 in patients 
with chronic HBV infection. Gastroenterology. 2019;156:1392-
1403.e7.
 14. Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of 48 
weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated 
interferon alfa-2a in patients with chronic HBV infection naive to 
nucleos(t)ide therapy. Gastroenterology. 2020;158:2180-2194.
 15. Liu Y, Jiang M, Xue J, Yan H, Liang X. Serum HBV RNA quantifi-
cation: useful for monitoring natural history of chronic hepatitis B 
infection. BMC Gastroenterol. 2019;19:53.
 16. Giersch K, Allweiss L, Volz T, Dandri M, Lutgehetmann M. Serum 
HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 
2017;66:460-462.
 17. Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in 
chronic HBV infection. J Viral Hepat. 2018;25:1038-1047.
 18. van Bommel F, van Bommel A, Krauel A, et al. Serum HBV RNA as a 
predictor of peginterferon alfa-2a response in patients with HBeAg-
positive chronic hepatitis B. J Infect Dis. 2018;218:1066-1074.
 19. van Bömmel F, Bartens A, Mysickova A, et al. Serum hepatitis B 
virus RNA levels as an early predictor of hepatitis B envelope an-
tigen seroconversion during treatment with polymerase inhibitors. 
Hepatology. 2015;61:66-76.
 20. Luo H, Tan N, Kang Q, et al. HBV pgRNA status can reveal the long-
term prognoses of chronic hepatitis B patients treated with nucle-
os(t)ide analogues. J Viral Hepat. 2020;27:323-328.
 21. Huang YW, Takahashi S, Tsuge M, et al. On-treatment low serum 
HBV RNA level predicts initial virological response in chronic hepa-
titis B patients receiving nucleoside analogue therapy. Antivir Ther. 
2015;20:369-375.
 22. Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, 
Zaaijer HL. Hepatitis B virus pregenomic RNA is present in virions 
in plasma and is associated with a response to pegylated interferon 
alfa-2a and nucleos(t)ide analogues. J Infect Dis. 2016;213:224-232.
 23. Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B 
virus RNA as early predictor for response to PEGylated interferon 
alfa in HBeAg negative chronic hepatitis B. Clin Infect Dis. 2020: 
ciaa013. https://doi.org/10.1093/cid/ciaa013.
 24. Campenhout MJH, Bömmel F, Pfefferkorn M, et al. Serum hepa-
titis B virus RNA predicts response to peginterferon treatment in 
HBeAg-positive chronic hepatitis B. J Viral Hepat. 2020;27:610-619.
 25. Yuen M-F, Agarwal K, Gane EJ, et al. Safety, pharmacokinetics, and 
antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a 
randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol 
Hepatol. 2020;5:152-166.
 26. Sonneveld MJ. Core inhibitor therapy for chronic hepatitis B. Lancet 
Gastroenterol Hepatol. 2020;5:99-100.
 27. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon 
alfa-2b alone or in combination with lamivudine for HBeAg-positive 
chronic hepatitis B: a randomised trial. Lancet. 2005;365:123-129.
 28. Rijckborst V, ter Borg MJ, Cakaloglu Y, et al. A randomized trial of 
peginterferon alpha-2a with or without ribavirin for HBeAg-negative 
chronic hepatitis B. Am J Gastroenterol. 2010;105:1762-1769.
 29. van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Host 
and viral factors associated with serum hepatitis B virus RNA levels 
among patients in need for treatment. Hepatology. 2018;68:839-847.
 30. Campenhout MJH, Rijckborst V, Brouwer WP, et al. Hepatitis B 
core-related antigen monitoring during peginterferon alfa treat-
ment for HBeAg-negative chronic hepatitis B. J Viral Hepat. 
2019;26:1156-1163.
 31. Datta S, Chatterjee S, Veer V, Chakravarty R. Molecular biol-
ogy of the hepatitis B virus for clinicians. J Clin Exp Hepatol. 
2012;2:353-365.
 32. Diab A, Foca A, Zoulim F, Durantel D, Andrisani O. The diverse 
functions of the hepatitis B core/capsid protein (HBc) in the viral life 
cycle: implications for the development of HBc-targeting antivirals. 
Antiviral Res. 2018;149:211-220.
 33. Luo H, Tan N, Kang Q, et al. Hepatitis B virus pregenomic RNA 
status can reveal the long-term prognoses of chronic hepati-
tis B patients treated with nucleos(t)ide analogues. J Viral Hepat. 
2020;27:323-328.
How to cite this article: Brakenhoff SM, de Man RA, Boonstra 
A, et al. Hepatitis B virus RNA decline without concomitant 
viral antigen decrease is associated with a low probability of 
sustained response and hepatitis B surface antigen loss. 
Aliment Pharmacol Ther. 2021;53:314–320. https://doi.
org/10.1111/apt.16172
